Literature DB >> 28748751

Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent.

Anshul Shakya1, Hans Raj Bhat1, Surajit Kumar Ghosh1.   

Abstract

BACKGROUND: The thiazolide nitazoxanide (NTZ) is a broad-spectrum antiinfective drug that adversely affects viability, growth, and proliferation of a range of extracellular and intracellular protozoan, helminths, anaerobic and microaerophilic bacteria, and viruses.
METHOD: Current review compiled the potential chemotherapeutic efficacy of NTZ against a variety of such disease-causing macro and/or micro-organisms as well as neoplastic cells, using various search engines viz. Web of Science, Scopus and Pub- Med up to February 2017. RESULT: The most accepted anti-infective mechanism of NTZ involves impairment of the energy metabolism in anaerobic pathogens by inhibition of the pyruvate: ferredoxin/ flavodoxin oxidoreductase (PFOR). In parasitic-protozoan NTZ also induces lesions/voids in the cell membrane and depolarises the mitochondrial membrane along with the inhibition of quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase. NTZ also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates a gene (avr-14 gene) encoding for the alphatype subunit of glutamate-gated chloride ion channel present in the nematodes. Apart from well recognized non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also showed a variety of other antibacterial mechanisms viz. inhibits pyruvate dehydrogenase in the Escherichia coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria and stimulates host macrophage autophagy in the tubercular patients. NTZ also suppresses the viral replication by inhibiting maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Additionally, NTZ expresses inhibitory effect on the tumour cell progression by modulating drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activities and c-Myc inhibition.
CONCLUSION: These potentially versatile molecular interactions of NTZ within invading pathogen(s) and immunomodulatory efficacy over the hosts, justify the multifunctional chemotherapeutic significance of this chemical agent. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Antiviral; anthelminthic; antibacterial; anticancer; antiprotozoal; thiazolide.

Mesh:

Substances:

Year:  2018        PMID: 28748751     DOI: 10.2174/1570163814666170727130003

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  18 in total

Review 1.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

2.  Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain.

Authors:  P Ripani; J Delp; K Bode; M E Delgado; L Dietrich; V M Betzler; N Yan; G von Scheven; T U Mayer; M Leist; T Brunner
Journal:  Oncogene       Date:  2019-12-16       Impact factor: 9.867

3.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

Review 4.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

5.  The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.

Authors:  Angelo Iacobino; Federico Giannoni; Manuela Pardini; Giovanni Piccaro; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

6.  Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.

Authors:  K F Walsh; K McAulay; M H Lee; S C Vilbrun; L Mathurin; D Jean Francois; M Zimmerman; F Kaya; N Zhang; K Saito; O Ocheretina; R Savic; V Dartois; W D Johnson; J W Pape; C Nathan; D W Fitzgerald
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.938

7.  In Vivo Treatment with the Combination of Nitazoxanide and Flubendazole Induces Gluconeogenesis and Protein Catabolism in Taenia crassiceps cysticerci.

Authors:  Nayana F Lima; Guaraciara A Picanço; Tatiane L Costa; Ruy de Souza Lino Junior; Marina C Vinaud
Journal:  Acta Parasitol       Date:  2020-08-05       Impact factor: 1.440

8.  Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs.

Authors:  Tasmia Ahmed; S M Abdur Rahman; Muhammad Asaduzzaman; Abul Bashar Mir Md Khademul Islam; A K Azad Chowdhury
Journal:  Pharmacol Res Perspect       Date:  2021-05

9.  Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors.

Authors:  Zirui Lü; Xiaona Li; Kebin Li; Cong Wang; Tingting Du; Wei Huang; Ming Ji; Changhong Li; Fengrong Xu; Ping Xu; Yan Niu
Journal:  ACS Med Chem Lett       Date:  2021-04-01       Impact factor: 4.345

Review 10.  Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Authors:  Dina B Mahmoud; Zayyanu Shitu; Ahmed Mostafa
Journal:  J Genet Eng Biotechnol       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.